# Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated (CoronaVac®) Vaccine in Healthy Adults in Turkey

> **NCT05150496** · PHASE2 · SUSPENDED · sponsor: **Sinovac Research and Development Co., Ltd.** · enrollment: 640 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated
- **BIOLOGICAL:** High-dose COVID-19 Vaccine(Vero Cell),Inactivated

## Key facts

- **NCT ID:** NCT05150496
- **Lead sponsor:** Sinovac Research and Development Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2022-12-15
- **Primary completion:** 2023-01-15
- **Final completion:** 2023-01-15
- **Target enrollment:** 640 (ESTIMATED)
- **Why stopped:** The plan has changed
- **Last updated:** 2022-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05150496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05150496, "Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated (CoronaVac®) Vaccine in Healthy Adults in Turkey". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05150496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*